Free Trial
→ Why Trump’s “Smart Dollar” could rewrite the rules (From Stansberry Research) (Ad)tc pixel Free BMY Stock Alerts

Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb logo
$46.22 -1.32 (-2.78%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$46.32 +0.09 (+0.21%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 21 Analyst Ratings
Sell
1
Hold
15
Buy
5

Based on 21 Wall Street analysts who have issued ratings for Bristol Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 1 has given a sell rating, 15 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for BMY.

Consensus Price Target

$56.38
21.97% Upside
According to the 21 analysts' twelve-month price targets for Bristol Myers Squibb, the average price target is $56.38. The highest price target for BMY is $73.00, while the lowest price target for BMY is $34.00. The average price target represents a forecasted upside of 21.97% from the current price of $46.22.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol Myers Squibb and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BMY Analyst Ratings Over Time

TypeCurrent Forecast
9/13/24 to 9/13/25		1 Month Ago
8/14/24 to 8/14/25		3 Months Ago
6/15/24 to 6/15/25		1 Year Ago
9/14/23 to 9/13/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
15 Hold rating(s)
15 Hold rating(s)
13 Hold rating(s)
13 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$56.38$56.38$58.00$54.67
Forecasted Upside21.97% Upside17.78% Upside16.69% Upside11.27% Upside
Consensus RatingHoldHoldHoldHold

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bristol Myers Squibb Stock vs. The Competition

TypeBristol Myers SquibbMedical CompaniesS&P 500
Consensus Rating Score
2.24
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside21.97% Upside17,477.86% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent BMY News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/5/2025Daiwa America
5 of 5 stars		 DowngradeStrong-Buy ➝ Hold
8/5/2025Daiwa Capital Markets
2 of 5 stars
Narumi Nakagiri
Not Rated
DowngradeOutperform ➝ Neutral$42.00-7.47%
8/1/2025Citigroup
2 of 5 stars
Andrew Baum
Not Rated
Lower TargetNeutral$51.00 ➝ $47.00+6.21%
7/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Terence Flynn
Terence Flynn
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingHold
4/25/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeHold
4/25/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingMarket Perform
4/23/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Akash Tewari
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetBuy$70.00 ➝ $68.00+36.49%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingNeutral$55.00 ➝ $55.00+12.36%
4/22/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
David Amsellem
David Amsellem
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageOverweight$65.00+32.79%
4/11/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Trung Huynh
Trung Huynh
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetNeutral$60.00 ➝ $54.00+8.43%
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$67.00 ➝ $55.00+1.97%
2/7/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetEqual Weight$60.00 ➝ $62.00+8.37%
1/8/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$62.00 ➝ $65.00+13.60%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingNeutral$63.00+7.25%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoveragePeer Perform
11/12/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetMarket Perform$57.00 ➝ $61.00+2.09%
11/12/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$55.00 ➝ $73.00+22.03%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageMarket Perform$56.00+4.93%
10/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
C. Gould
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetUnderweight$42.00 ➝ $43.00-20.25%
10/7/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetHold$53.00 ➝ $59.00+9.32%
7/23/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetHold$53.00 ➝ $45.00+5.36%
3/11/2024Societe Generale
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Hold
2/6/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Neutral$77.00 ➝ $54.00+12.50%
10/27/2023HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeReduce ➝ Hold$55.00 ➝ $53.00+0.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:25 PM ET.


Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these Bristol Myers Squibb pros and cons to contact@marketbeat.com.

Bristol Myers Squibb
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

  • The company reported strong quarterly earnings, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future growth.
  • The current stock price is around $70, reflecting a solid position in the market and potential for appreciation as the company continues to innovate.
  • The company has a high return on equity, suggesting effective management and the ability to generate profits from shareholders' investments.
  • Bristol-Myers Squibb offers a competitive dividend yield of approximately 5.2%, providing investors with a steady income stream in addition to potential capital gains.

Bristol Myers Squibb
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

  • The company has a high dividend payout ratio of 100%, which may raise concerns about sustainability, especially if earnings fluctuate.
  • Recent revenue growth was modest, indicating potential challenges in maintaining momentum in a competitive biopharmaceutical market.
  • There are ongoing regulatory challenges and market pressures that could impact the approval and sales of new products.
  • Investors may face volatility in stock performance due to market reactions to clinical trial results and product launches.
  • Dependence on a few key products for revenue could pose risks if those products face competition or regulatory hurdles.

BMY Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol Myers Squibb is $56.38, with a high forecast of $73.00 and a low forecast of $34.00.

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bristol Myers Squibb in the last twelve months. There is currently 1 sell rating, 15 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.

According to analysts, Bristol Myers Squibb's stock has a predicted upside of 21.97% based on their 12-month stock forecasts.

Over the previous 90 days, Bristol Myers Squibb's stock had 2 downgrades by analysts.

Bristol Myers Squibb has been rated by research analysts at Citigroup, Daiwa America, Daiwa Capital Markets, and Morgan Stanley in the past 90 days.

Analysts like Bristol Myers Squibb less than other "medical" companies. The consensus rating for Bristol Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:BMY) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel